Quentis Therapeutics Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Employees
  • 16
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $1M
Latest Deal Amount
  • Investors
  • 10

Quentis Therapeutics General Information

Description

Developer of immuno-therapeutics designed to translate novel biology into new therapeutic approaches. The company's therapeutics are designed to target endoplasmic reticulum (ER) stress pathways and awaken the immune system's ability to fight the tumor, enabling patients to boost anti-tumor immunity in cancer

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 430 East 29th Street
  • Suite 1005
  • New York, NY 10016
  • United States

Quentis Therapeutics Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Quentis Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 03-Dec-2018 $1M 000.00 Completed Product Development
4. Accelerator/Incubator 01-Sep-2018 000.00 Completed Product Development
3. Early Stage VC (Series A) 27-Feb-2018 000.00 000.00 000.00 Completed Product Development
2. Seed Round 22-Nov-2017 $2M $5M 0000 Completed Startup
1. Seed Round 09-Jun-2016 $3M $3M 000 Completed Startup
To view Quentis Therapeutics’s complete valuation and funding history, request access »

Quentis Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Seed 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
To view Quentis Therapeutics’s complete cap table history, request access »

Quentis Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of immuno-therapeutics designed to translate novel biology into new therapeutic approaches. The company's ther
Biotechnology
New York, NY
16 As of 2018
000.00
0000000000 000.00

00000000

etur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
0000000000000
Culver City, CA
000 As of 0000
00000
000000000000 00000

00000000

nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Quentis Therapeutics Competitors (43)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ImmunityBio Venture Capital-Backed Culver City, CA 000 00000 000000000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000 Venture Capital-Backed Lebanon, NH 000 00000 0000000000 0 00000
0000 Formerly VC-backed Emeryville, CA 00 00000 00000000 00000
000000000 00000000 Venture Capital-Backed Salt Lake City, UT 000 00000 00000000000 00000
You’re viewing 5 of 43 competitors. Get the full list »

Quentis Therapeutics Executive Team (7)

Name Title Board Seat Contact Info
David Feldman Director, Finance & Operations
Joseph Vacca Ph.D Head of Chemistry
Laurie Glimcher MD Scientific Co-Founder & Chairman of Scientific Advisory Board
You’re viewing 3 of 7 executive team members. Get the full list »

Quentis Therapeutics Board Members (7)

Name Representing Role Since
Amy Schulman JD Polaris Partners Board Member 000 0000
Carlo Rizzuto Ph.D Versant Venture Board Member 000 0000
Laurie Glimcher MD Self Scientific Co-Founder & Chairman of Scientific Advisory Board 000 0000
Mark Murcko Ph.D Self Board Member 000 0000
Michael Foley Ph.D Quentis Therapeutics Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Quentis Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Quentis Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
New York City Economic Development Government 000 0000 000000 0
JLABS Accelerator/Incubator Minority 000 0000 000000 0
AbbVie Ventures Corporate Venture Capital Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
New York Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »